05/13/2013
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
05/08/2013
Complex protein therapeutics like monoclonal antibodies (mAbs) require comprehensive testing of the biological activity during the whole life cycle to ensure quality, safety and efficacy. For this purpose, functional bioassays reflecting a drug’s mode of action (MoA) are required by the regulatory authorities.
05/02/2013
Charles River has developed and optimized the RT-PCR test for vertically-transmitted poultry pathogens for testing SPF flocks as defined by the PhEur 5.2.2.
04/29/2013
Our newly installed AB SCIEX QTrap® 6500 is the most sensitive mass spectrometer on the market and allows our scientists access to the highest level of LC-MS/MS performance for drug quantitation.
04/15/2013
The Charles River Animal Welfare department has made recent strides in further integrating the 3Rs into our operations. Charles River representatives are acting as ambassadors within the industry to elevate the importance of animal welfare in laboratory animal research.
04/15/2013
Through this agreement, Charles River will sell the Axcess™ System, an offering that combines the Bruker MALDI Biotyper system with a custom data analysis software solution that allows instantaneous access to the Accugenix® microbial database for identifications.
04/11/2013
Clinical pathology data, such as hematology and clinical chemistry, can not only assist researchers in selecting the most appropriate model for their study, but it can also provide important information on the physiology and health of research animals.
04/08/2013
We now offer OCT to allow for imaging of ocular structures during the in-life phase of preclinical studies. OCT offers a potential advantage for the reduction of the number of animals required per study.
04/01/2013
We have recently expanded our xenograft portfolio to now include early-passage xenografts derived from fresh surgical tumor specimens. These patient-derived xenografts, or PDX models, offer advantages over conventional models.
03/29/2013
We have reached an agreement with Lohmann Animal Health, Int. to purchase and transfer their USDA-licensed Salmonella pullorum plate antigen to our laboratories. This license transfer will allow for a more rapid approval by the USDA.